Aberdeen, United Kingdom

Björn Olaf Schelter

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovations of Bjorn Olaf Schelter

Introduction

Bjorn Olaf Schelter is a notable inventor based in Aberdeen, GB. He has made significant contributions to the field of neurodegenerative disorder treatments, holding a total of 8 patents. His work focuses on optimizing dosage regimens for specific compounds that can enhance therapeutic efficacy.

Latest Patents

One of his latest patents is titled "Optimised dosage of diaminophenothiazines in populations." This invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds. The goal is to maximize the proportion of subjects in which the MT concentration will exceed levels necessary for therapeutic efficacy in treating neurodegenerative disorders such as Alzheimer's disease and frontotemporal dementias. The invention also includes LMT-containing dosage units and other compositions. Another significant patent is "Administration and dosage of diaminophenothiazines." This invention outlines novel regimens for treating neurodegenerative disorders using methylthioninium (MT)-containing compounds. These regimens are based on new findings regarding the dosage of MT compounds and their interaction with symptomatic treatments that modulate acetylcholinesterase levels.

Career Highlights

Bjorn Olaf Schelter is associated with Wista Laboratories Ltd., where he continues to innovate in the field of medical treatments. His work has the potential to significantly impact the lives of individuals suffering from neurodegenerative diseases.

Collaborations

He has collaborated with notable individuals in his field, including Claude Michel Wischik and Damon Jude Wischik. Their combined expertise contributes to the advancement of research and development in neurodegenerative disorder treatments.

Conclusion

Bjorn Olaf Schelter's contributions to the field of neurodegenerative disorder treatments through his innovative patents highlight his dedication to improving patient outcomes. His work continues to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…